Anti Angiogenesis
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC (NCT06475755) | Tang-Du Hospital | 2024-06-30 |
| Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation (NCT05460195) | Shanghai Chest Hospital | 2022-01-01 |
Track Anti Angiogenesis automatically
Every clearance here is in the API, with alerts when new ones post.